The payer landscape is shifting fast. Here’s what’s changed, what’s at risk, and how your team should respond.
The denials environment your team navigated in 2025 looks different today. New payer policies, federal regulatory changes, and the accelerating role of AI in utilization review have reshaped the rules—and the revenue at stake is too significant to absorb through business as usual.
These changes are already in effect. Here’s what your team needs to know, payer by payer.
The AI Problem No One Is Talking About Enough
Health plans have fully committed to AI-powered utilization review—and that means more denials generated faster, with less patient-specific reasoning behind them.
The pattern is consistent: algorithm-generated denial language, guideline mismatch citations, minimal clinical context. These systems are built for pattern-matching, not nuance. They’re not weighing comorbidities, catching early deterioration, or accounting for the clinical judgment that led a provider to escalate care in the first place.
That gap is where your appeals team has to operate.
MCG and InterQual remain your foundation. But anchoring appeals entirely in criteria language plays directly into the algorithm’s logic. Your strongest cases go further—they tell the story the system can’t read: the patient whose outpatient course already failed, the one whose instability made a lower level of care genuinely unsafe, the one whose readmission risk was too real to ignore.
Clinical storytelling isn’t a soft skill anymore. It’s your most effective appeals tool.
To view the Payer Policy Playbook, click here:
Medicare IPO List: The Foundation Just Changed
If your team has been relying on Inpatient-Only (IPO) list status as an anchor for inpatient appeals, that anchor is gone for a growing number of procedures.
CMS eliminated 285 musculoskeletal and related surgical procedures from the IPO list—including complex orthopedic and spine codes—with full phase-out of the entire list by January 2028. The absence of a procedure from that list is not, on its own, a winning appeals argument.
With IPO protections removed, every admission must now be justified on clinical merits: the two-midnight benchmark, clinical risk and complexity, post-operative care needs, and documentation supporting the patient’s recovery trajectory.
The shift your team needs to make: Stop anchoring IPO appeals in list status. Ground inpatient determinations in CMS medical necessity standards, backed by MCG or InterQual, built around the clinical picture of the specific patient.
Aetna: The Midnight Threshold That Changes Everything
Aetna’s Level of Severity Inpatient Payment Policy introduced a two-tier reimbursement model for Medicare Advantage and Special Needs Plan members. The mechanics matter here.
Stays of five or more midnights will not undergo severity review and will be paid at the full inpatient DRG rate. If one of these cases is downgraded or denied, that’s a policy violation—challenge it immediately citing Aetna’s own terms.
Stays of one to four midnights undergo a level-of-severity review using MCG criteria. Aetna will still approve the inpatient admission, but if the case is judged low severity, payment downgrades to a rate similar to observation. The admission stands; the revenue takes the hit.
Bottom line: Flag any downgrade on five-plus midnight cases immediately. For one-to-four midnight cases, tailor your appeal to MCG inpatient criteria and severity factors. These cases may appear paid as inpatient—but they’re being reimbursed at a lower level of care. Appeal at the level billed.
Anthem Medicare Advantage: Peer-to-Peer Is No Longer an Off-Ramp
Anthem Medicare Advantage will no longer allow denials to be overturned through peer-to-peer review. Once an inpatient admission or length-of-stay denial is issued, the only path is the formal appeal process.
This changes your workflow, not your rights. CMS rules place limits on Medicare Advantage plans’ ability to retroactively reclassify previously approved inpatient admissions, particularly when medical necessity was established and documented. That protection is real and enforceable.
Anthem is also increasing documentation requirements for complex cases, and incomplete records during prior coverage transitions will drive more denials.
Operationally: Eliminate peer-to-peer from your Anthem MA workflow and redirect those resources to appeal preparation. The CMS guardrails on retroactive downgrades may also support retraction arguments against Medicare Advantage plans.
CMS: Two Rules That Cut in Different Directions
The 2026 federal regulatory environment created both protections and new exposures.
On the protection side: CMS prohibits MA plans from retroactively downgrading an approved inpatient admission without clear evidence of fraud or obvious administrative error. Cite this whenever a payer attempts a retroactive denial of an already-approved stay.
On the exposure side: CMS implementation of Medicare drug price negotiation is pushing payers toward tighter formulary controls. Expect more step-therapy denials and stricter preferred-drug enforcement. When a patient can’t use the preferred agent, document clinical need specifically and thoroughly.
Blue Cross Blue Shield: More Drug Denials, Stricter Biosimilar Requirements
BCBS plans are removing coverage for a significant range of medications—ADHD drugs (Adderall XR, Concerta, Vyvanse), migraine medications (Almotriptan), GI drugs (Alosetron 1mg), topical anti-inflammatories, and multiple inflammatory biologics. North Carolina Blue Cross is also moving to biosimilar-first requirements, preferring Epysqli for eculizumab products and Denosumab biosimilars Jubbonti, Stoboclo, Wyost, and Osenvelt over Prolia/Xgeva—resulting in more preferred-agent and step-therapy denials.
What to prepare for: Appeals for nonpreferred therapies need clear documentation of why the patient cannot safely transition to the preferred biosimilar. Alternative-failure documentation must be specific and in the record before the claim is submitted.
Humana: Fewer Prior Auths, More Downstream Risk
Humana removed roughly one-third of outpatient prior authorizations—CT/MRI, colonoscopies, transthoracic echocardiograms. That may look like relief. It isn’t.
The risk shifted to the back end. Humana is simultaneously tightening coding-driven claim edits and expanding technical edits for biosimilars, NICU services, and biomarker testing—areas where missing modifiers, incomplete test justification, or mismatched documentation routinely trigger denials after the fact.
Where to focus: Internal audits on coding accuracy and documentation completeness. The reduction in prior authorizations doesn’t reduce your exposure—it relocates it.
United Healthcare: Technical Denials Are the New Normal
UHC’s 2026 updates signal a clear shift toward post-claim technical auditing. New coding rules rolled out in phases: anatomical modifier requirements; ICD-10 excludes conflict edits, and stricter radiology documentation standards. UHC is also expanding prior authorization requirements for high-cost injectables, gene therapies, and immune globulins.
The challenge: technical denials hit even when clinical necessity is fully supported. A well-documented case gets denied because a modifier is missing, or radiology documentation doesn’t clear the new threshold.
Where to focus: Modifier accuracy, thorough radiology documentation, and pre-submission review of high-cost drug claims. Documentation completeness is the deciding factor.
The Through-Line for 2026
What connects all of these changes is a consistent shift of complexity onto providers. Payers are building systems that are faster, more standardized, and less forgiving of gaps in clinical documentation and coding specificity.
The teams that recover revenue in this environment will be the ones who go beyond criteria citations—building appeals that tell the full clinical story, staying ahead of technical requirements, and knowing payer-specific policies well enough to cite them in the challenge. As automated review expands, that approach isn’t optional. It’s the standard.
Aspirion’s appeals team combines clinical expertise, legal strategy, and AI-powered automation to help hospitals and health systems recover revenue from their most challenging denials. Ready to discuss what 2026 means for your organization? Let’s talk.
